Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0325-2027

CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010 Recall

CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010

FDA recall Class II

Ongoing

FDA lists this Class II recall for CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0325-2027
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Sep 18, 2026
FDA report date
Nov 11, 2026
Quantity in commerce
1
Distribution
See key details
FDA cause
Nonconforming Material/Component

What is being recalled?

CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010

Affected model & UDI checker

Search the exact identifiers published for Z-0325-2027.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
SGP010CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010Check source noticeNot specified
FDA code information

Serial/Donor Number: 12617554/177871, UDI-DI: 00877234000478, Shipped: 22May2024, Implanted: 05June2024

View the original FDA recall notice

Why was this product recalled?

A cryopreserved pulmonary human cardiac patch, taken from a 64-year-old human donor, was outside the cardiac tissue donor age specification of newborn to 60 years. The patch was implanted, and due to limitations of long-term in vivo data, the possibility of premature graft dysfunction cannot be excluded.

What actions did Artivion, Inc take?

On 9/18/2026, the notification was delivered via mail to customer who was advised of the following: Available biomechanical and histological evidence does not indicate an increased risk that would warrant additional patient testing, enhanced clinical monitoring, or other clinical intervention beyond the patient's routine standard of care. Accordingly, prophylactic removal or surgical replacement of the already implanted tissue solely because of the donor-age nonconformance is not clinically warranted. Complete and return the response form via email to [email protected] Firm requests that any observed deficiency, performance concern, or other issue potentially associated with the tissue be reported to them vial email: [email protected] or phone: +1-770-419-3355

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology